--- title: "Pre-market hot trades in US stocks: Applied Materials down 3.38% in pre-market; KLA down 3.25% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/292897099.md" description: "Applied Materials pre-market down 3.38%; KLA pre-market down 3.25%; The Growhub pre-market up 59.61%; Liminatus Pharma pre-market up 38.86%; AtaiBeckley pre-market up 34.14%" datetime: "2026-07-16T11:22:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292897099.md) - [en](https://longbridge.com/en/news/292897099.md) - [zh-HK](https://longbridge.com/zh-HK/news/292897099.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Applied Materials down 3.38% in pre-market; KLA down 3.25% in pre-market **Pre-market Hot Trades in US Stocks** Applied Materials fell 3.38% in pre-market trading. Based on recent key news: 1. On July 13, Goldman Sachs released a research report maintaining a "Buy" rating for Applied Materials and raised the 12-month target price from $520 to $645. Goldman Sachs is optimistic about the long-term growth potential brought by DRAM and HBM, believing that the company's order visibility extends to 2028, and that the 2nm process and advanced packaging business are expected to drive performance beyond peers. This news attracted market attention, causing the stock price to drop nearly 5% during the session. Source: Zhitong Finance 2. On July 15, Citigroup raised the target price for Applied Materials from $570 to $705, maintaining a "Buy" rating. This move reflects market confidence in Applied Materials' future growth, although the stock price still fell in pre-market trading. Source: Gelonghui 3. On July 13, TD Cowen raised the target price for Applied Materials from $525 to $700, while Mizuho Securities raised its target price to $650. Analysts pointed out that the long-term growth potential of Applied Materials has not been fully priced in, and the market holds an optimistic view of its future performance. Source: Wall Street Insight KLA fell 3.25% in pre-market trading. Based on recent key news: 1. On July 13, KLA faced a 100 basis point gross margin pressure, primarily due to rising input costs for high-speed DRAM memory chips required in its dedicated testing and measurement systems. This cost increase directly impacted the company's profitability. 2. On July 15, KLA's BDR program in Brazil will execute a mandatory 4-for-1 stock split, with each BDR receiving 4 additional BDRs. This split may lead to short-term volatility in the company's stock. 3. On July 14, market analysis showed that despite strong AI demand, the recovery in the traditional PC and smartphone markets is slow, leading to a decline in wafer fab utilization, and customers may delay high-margin service contracts and equipment upgrades. Strong AI demand, but slow recovery in the PC market. **Top Gainers in Pre-market US Stocks** The Growhub rose 59.61% in pre-market trading. Based on recent key news: 1. On July 15, The Growhub Ltd. released important information through the EDGAR system of the U.S. Securities and Exchange Commission. The release of this information may have triggered positive market expectations for the company's future development, leading to a significant rise in stock price. Source: EDGAR system 2. No other significant news recently. The market reacted positively to the company's information, resulting in significant stock price fluctuations. Liminatus Pharma rose 38.86% in pre-market trading, with no important news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation AtaiBeckley pre-market rose 34.14%. Based on recent key news: 1. On July 16, Eli Lilly announced it would acquire AtaiBeckley for $6.75 per share in cash, with a total transaction value of approximately $2.8 billion. This news significantly boosted AtaiBeckley's stock price. 2. On July 15, Bloomberg reported that Eli Lilly was in acquisition talks with AtaiBeckley, expecting to conduct the transaction at a premium. This news sparked strong market interest in AtaiBeckley, with the stock price soaring 66% in after-hours trading. 3. On July 16, AtaiBeckley's core product BPL-003 received breakthrough therapy designation from the U.S. FDA and initiated preparations for Phase III clinical trials, further enhancing market confidence in its future development. The psychedelic drug industry is supported by policies, with significant capital inflow ### Related Stocks - [AMAT.US](https://longbridge.com/en/quote/AMAT.US.md) - [KLAC.US](https://longbridge.com/en/quote/KLAC.US.md) - [TGHL.US](https://longbridge.com/en/quote/TGHL.US.md) - [LIMN.US](https://longbridge.com/en/quote/LIMN.US.md) - [ATAI.US](https://longbridge.com/en/quote/ATAI.US.md) ## Related News & Research - [Applied Materials Stock Is Down on Earnings. Here’s What Barchart Options Data Says Could Come Next for AMAT.](https://longbridge.com/en/news/295967382.md) - [Applied Materials stock falls after earnings weren’t quite good enough](https://longbridge.com/en/news/295845302.md) - [WealthShield Partners LLC Makes New Investment in Entergy Corporation $ETR](https://longbridge.com/en/news/296699070.md) - [Keysight sees bullish views from analysts after Q3 results, outlook](https://longbridge.com/en/news/296363842.md) - [Anthropic Plans to Expand Revolving Credit Line to Over $10 Billion Ahead of IPO](https://longbridge.com/en/news/296257817.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**